-
2025-521762-99-00
5
2026-03-09
acute ischemic stroke
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2024-519404-27-00
5
2026-01-16
IDH-mutant grade 2 or 3 astrocytoma
-
2022-500676-59-00
4
2025-12-18
EBV-positive nasopharyngeal carcinoma
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-515982-32-00
6
2025-12-09
Overweight or Obesity
-
2024-519913-76-00
4
2025-12-09
PDL1-negative metastatic triple-negative breast cancer
-
2025-521349-25-00
5
2025-12-09
Macular neovascularization secondary to age-related macular degenerati
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2024-517977-26-00
5
2025-11-25
acute decompensated heart failure
-
2024-520219-42-00
10
2025-11-18
ivosidenib maintenance after SOC adjuvant chemotherapy in curative mID
-
2024-512849-17-00
5
2025-11-14
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-518008-33-00
5
2025-11-12
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-518156-24-00
5
2025-11-10
Atopic Dermatitis
-
2025-521260-35-00
6
2025-11-07
acute ischemic stroke and atrial fibrillation (AF)
-
2024-520290-12-00
6
2025-11-04
Hormone receptor–positive (HRpos)/human epidermal growth factor recept